1. Kurowska-Stolarska M, Hueber A, Stolarski B, McInnes IB. Interleukin-33: a novel mediator with a role in distinct disease pathologies. J Intern Med 2011;269:29-35. PMID:
21158975
3. Luthi AU, Cullen SP, McNeela EA, Duriez PJ, Afonina IS, Sheridan C, et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity 2009;31:84-98. PMID:
19559631
5. Tago K, Noda T, Hayakawa M, Iwahana H, Yanagisawa K, Yashiro T, et al. Tissue distribution and subcellular localization of a variant form of the human ST2 gene product, ST2V. Biochem Biophys Res Commun 2001;285:1377-83. PMID:
11478810
6. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005;23:479-90. PMID:
16286016
7. Ho LH, Ohno T, Oboki K, Kajiwara N, Suto H, Iikura M, et al. IL-33 induces IL-13 production by mouse mast cells independently of IgE-FcepsilonRI signals. J Leukoc Biol 2007;82:1481-90. PMID:
17881510
8. Kondo Y, Yoshimoto T, Yasuda K, Futatsugi-Yumikura S, Morimoto M, Hayashi N, et al. Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system. Int Immunol 2008;20:791-800. PMID:
18448455
9. Smithgall MD, Comeau MR, Yoon BR, Kaufman D, Armitage R, Smith DE. IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol 2008;20:1019-30. PMID:
18550585
10. Smith DE. IL-33: a tissue derived cytokine pathway involved in allergic inflammation and asthma. Clin Exp Allergy 2010;40:200-8. PMID:
19906013
11. Matsuba-Kitamura S, Yoshimoto T, Yasuda K, Futatsugi-Yumikura S, Taki Y, Muto T, et al. Contribution of IL-33 to induction and augmentation of experimental allergic conjunctivitis. Int Immunol 2010;22:479-89. PMID:
20501612
13. Iikura M, Suto H, Kajiwara N, Oboki K, Ohno T, Okayama Y, et al. IL-33 can promote survival, adhesion and cytokine production in human mast cells. Lab Invest 2007;87:971-8. PMID:
17700564
17. Sayed BA, Christy A, Quirion MR, Brown MA. The master switch: the role of mast cells in autoimmunity and tolerance. Annu Rev Immunol 2008;26:705-39. PMID:
18370925
18. Haenuki Y, Matsushita K, Futatsugi-Yumikura S, Ishii KJ, Kawagoe T, Imoto Y, et al. A critical role of IL-33 in experimental allergic rhinitis. J Allergy Clin Immunol 2012;130:184-94.e11. PMID:
22460070
19. Belpinati F, Malerba G, Trabetti E, Galavotti R, Xumerle L, Pescollderungg L, et al. Association of childhood allergic asthma with markers flanking the IL33 gene in Italian families. J Allergy Clin Immunol 2011;128:667-8. PMID:
21802127
20. Bonnelykke K, Sleiman P, Nielsen K, Kreiner-Moller E, Mercader JM, Belgrave D, et al. A genome-wide association study identifies CDHR3 as a susceptibility locus for early childhood asthma with severe exacerbations. Nat Genet 2014;46:51-5. PMID:
24241537
22. Gudbjartsson DF, Bjornsdottir US, Halapi E, Helgadottir A, Sulem P, Jonsdottir GM, et al. Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat Genet 2009;41:342-7. PMID:
19198610
23. Hirota T, Takahashi A, Kubo M, Tsunoda T, Tomita K, Sakashita M, et al. Genome-wide association study identifies eight new susceptibility loci for atopic dermatitis in the Japanese population. Nat Genet 2012;44:1222-6. PMID:
23042114
25. Li J, Zhang Y, Zhang L. Discovering susceptibility genes for allergic rhinitis and allergy using a genome-wide association study strategy. Curr Opin Allergy Clin Immunol 2015;15:33-40. PMID:
25304232
27. Ramasamy A, Kuokkanen M, Vedantam S, Gajdos ZK, Couto Alves A, Lyon HN, et al. Genome-wide association studies of asthma in population-based cohorts confirm known and suggested loci and identify an additional association near HLA. PLoS One 2012;7:e44008.
28. Savenije OE, Mahachie John JM, Granell R, Kerkhof M, Dijk FN, de Jongste JC, et al. Association of IL33-IL-1 receptor-like 1 (IL-1RL1) pathway polymorphisms with wheezing phenotypes and asthma in childhood. J Allergy Clin Immunol 2014;134:170-7. PMID:
24568840
29. Shimizu M, Matsuda A, Yanagisawa K, Hirota T, Akahoshi M, Inomata N, et al. Functional SNPs in the distal promoter of the ST2 gene are associated with atopic dermatitis. Hum Mol Genet 2005;14:2919-27. PMID:
16118232
31. Prefontaine D, Nadigel J, Chouiali F, Audusseau S, Semlali A, Chakir J, et al. Increased IL-33 expression by epithelial cells in bronchial asthma. J Allergy Clin Immunol 2010;125:752-4. PMID:
20153038
32. Asaka D, Yoshikawa M, Nakayama T, Yoshimura T, Moriyama H, Otori N. Elevated levels of interleukin-33 in the nasal secretions of patients with allergic rhinitis. Int Arch Allergy Immunol 2012;158 Suppl 1:47-50. PMID:
22627366
34. Savinko T, Matikainen S, Saarialho-Kere U, Lehto M, Wang G, Lehtimäki S, et al. IL-33 and ST2 in atopic dermatitis: expression profiles and modulation by triggering factors. J Invest Dermatol 2012;132:1392-400. PMID:
22277940
35. Tamagawa-Mineoka R, Okuzawa Y, Masuda K, Katoh N. Increased serum levels of interleukin 33 in patients with atopic dermatitis. J Am Acad Dermatol 2014;70:882-8. PMID:
24569114
36. Hueber AJ, Alves-Filho JC, Asquith DL, Michels C, Millar NL, Reilly JH, et al. IL-33 induces skin inflammation with mast cell and neutrophil activation. Eur J Immunol 2011;41:2229-37. PMID:
21674479
38. Nabe T. Interleukin (IL)-33: new therapeutic target for atopic diseases. J Pharmacol Sci 2014;126:85-91. PMID:
25213717
39. Wang S, Ding L, Liu SS, Wang C, Leng RX, Chen GM, et al. IL-33: a potential therapeutic target in autoimmune diseases. J Investig Med 2012;60:1151-6. PMID:
23076162
40. Lohning M, Stroehmann A, Coyle AJ, Grogan JL, Lin S, Gutierrez-Ramos JC, et al. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci USA 1998;95:6930-5. PMID:
9618516
42. Lee HY, Rhee CK, Kang JY, Byun JH, Choi JY, Kim SJ, et al. Blockade of IL-33/ST2 ameliorates airway inflammation in a murine model of allergic asthma. Exp Lung Res 2014;40:66-76. PMID:
24446582
44. McLean MH, Neurath MF, Durum SK. Targeting interleukins for the treatment of inflammatory bowel disease-what lies beyond anti-TNF therapy? Inflamm Bowel Dis 2014;20:389-97. PMID:
24356385
46. Liu X, Zhu L, Lu X, Bian H, Wu X, Yang W, et al. IL-33/ST2 pathway contributes to metastasis of human colorectal cancer. Biochem Biophys Res Commun 2014;453:486-92. PMID:
25280997
47. Yu XX, Hu Z, Shen X, Dong LY, Zhou WZ, Hu WH. IL-33 Promotes Gastric Cancer Cell Invasion and Migration Via ST2-ERK1/2 Pathway. Dig Dis Sci 2015;60:1265-72. PMID:
25655003
49. Pomeshchik Y, Kidin I, Korhonen P, Savchenko E, Jaronen M, Lehtonen S, et al. Interleukin-33 treatment reduces secondary injury and improves functional recovery after contusion spinal cord injury. Brain Behav Immun 2015;44:68-81. PMID:
25153903
54. Choi YS, Park JA, Kim J, Rho SS, Park H, Kim YM, et al. Nuclear IL-33 is a transcriptional regulator of NF-κB p65 and induces endothelial cell activation. Biochem Biophys Res Commun 2012;421:305-11. PMID:
22708120
55. Saluja R, Hawro T, Eberle J, Church MK, Maurer M. Interleukin-33 promotes the proliferation of mouse mast cells through ST2/MyD88 and p38 MAPK-dependent and Kit-independent pathways. J Biol Regul Homeost Agents 2014;28:575-85. PMID:
25620169
57. Allakhverdi Z, Smith DE, Comeau MR, Delespesse G. Cutting edge: The ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J Immunol 2007;179:2051-4. PMID:
17675461
58. Enoksson M, Lyberg K, Moller-Westerberg C, Fallon PG, Nilsson G, Lunderius-Andersson C. Mast cells as sensors of cell injury through IL-33 recognition. J Immunol 2011;186:2523-8. PMID:
21239713
59. Moulin D, Donze O, Talabot-Ayer D, Mezin F, Palmer G, Gabay C. Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine 2007;40:216-25. PMID:
18023358
60. Xu D, Jiang HR, Li Y, Pushparaj PN, Kurowska-Stolarska M, Leung BP, et al. IL-33 exacerbates autoantibody-induced arthritis. J Immunol 2010;184:2620-6. PMID:
20139274
61. Eklund KK. Mast cells in the pathogenesis of rheumatic diseases and as potential targets for anti-rheumatic therapy. Immunol Rev 2007;217:38-52. PMID:
17498050
62. Enoksson M, Moller-Westerberg C, Wicher G, Fallon PG, Forsberg-Nilsson K, Lunderius-Andersson C, et al. Intraperitoneal influx of neutrophils in response to IL-33 is mast cell-dependent. Blood 2013;121:530-6. PMID:
23093619
65. Silver MR, Margulis A, Wood N, Goldman SJ, Kasaian M, Chaudhary D. IL-33 synergizes with IgE-dependent and IgE-independent agents to promote mast cell and basophil activation. Inflamm Res 2010;59:207-18. PMID:
19763788
68. Chu Y, Vahl JC, Kumar D, Heger K, Bertossi A, Wojtowicz E, et al. B cells lacking the tumor suppressor TNFAIP3/A20 display impaired differentiation and hyperactivation and cause inflammation and autoimmunity in aged mice. Blood 2011;117:2227-36. PMID:
21088135
70. Kool M, van Loo G, Waelput W, De Prijck S, Muskens F, Sze M, et al. The ubiquitin-editing protein A20 prevents dendritic cell activation, recognition of apoptotic cells, and systemic autoimmunity. Immunity 2011;35:82-96. PMID:
21723156
71. Matmati M, Jacques P, Maelfait J, Verheugen E, Kool M, Sze M, et al. A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis. Nat Genet 2011;43:908-12. PMID:
21841782
75. Palmer G, Talabot-Ayer D, Lamacchia C, Toy D, Seemayer CA, Viatte S, et al. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum 2009;60:738-49. PMID:
19248109
77. Kiss A, Montes M, Susarla S, Jaensson EA, Drouin SM, Wetsel RA, et al. A new mechanism regulating the initiation of allergic airway inflammation. J Allergy Clin Immunol 2007;120:334-42. PMID:
17544098
79. Theoharides TC, Kempuraj D, Sant GR. Mast cell involvement in interstitial cystitis: a review of human and experimental evidence. Urology 2001;57(6 Suppl 1):47-55. PMID:
11378050
81. Kochiashvili G, Kochiashvili D. Urinary IL-33 and galectin-3 increase in patients with interstitial cystitis/bladder pain syndrome (review). Georgian Med News 2014;((232-233)):12-5.
82. Sant GR, Kempuraj D, Marchand JE, Theoharides TC. The mast cell in interstitial cystitis: role in pathophysiology and pathogenesis. Urology 2007;69(4 Suppl):34-40.
83. Sant GR, Theoharides TC. The role of the mast cell in interstitial cystitis. Urol Clin North Am 1994;21:41-53. PMID:
8284844
84. Simmons JL, Bunce PL. On the use of an antihistamine in the treatment of interstitial cystitis. Am Surg 1958;24:664-7. PMID:
13571617
85. Choi BH, Jin LH, Kim KH, Han JY, Kang JH, Yoon SM, et al. Mast cell activation and response to tolterodine in the rat urinary bladder in a chronic model of intravesical protamine sulfate and bacterial endotoxin-induced cystitis. Mol Med Rep 2014;10:670-6. PMID:
24859757
86. Larsen S, Thompson SA, Hald T, Barnard RJ, Gilpin CJ, Dixon JS, et al. Mast cells in interstitial cystitis. Br J Urol 1982;54:283-6. PMID:
7104591
87. Feltis JT, Perez-Marrero R, Emerson LE. Increased mast cells of the bladder in suspected cases of interstitial cystitis: a possible disease marker. J Urol 1987;138:42-3. PMID:
3599216
88. Aldenborg F, Fall M, Enerback L. Proliferation and transepithelial migration of mucosal mast cells in interstitial cystitis. Immunology 1986;58:411-6. PMID:
3733146
89. Lynes WL, Flynn SD, Shortliffe LD, Lemmers M, Zipser R, Roberts LJ 2nd, et al. Mast cell involvement in interstitial cystitis. J Urol 1987;138:746-52. PMID:
3477649
90. Johansson SL, Fall M. Clinical features and spectrum of light microscopic changes in interstitial cystitis. J Urol 1990;143:1118-24. PMID:
2342171
91. Enerback L, Fall M, Aldenborg F. Histamine and mucosal mast cells in interstitial cystitis. Agents Actions 1989;27:113-6. PMID:
2750582
92. Bullock AD, Becich MJ, Klutke CG, Ratliff TL. Experimental autoimmune cystitis: a potential murine model for ulcerative interstitial cystitis. J Urol 1992;148:1951-6. PMID:
1433651
93. Christensen MM, Keith I, Rhodes PR, Graziano FM, Madsen PO, Bruskewitz RC, et al. A guinea pig model for study of bladder mast cell function: histamine release and smooth muscle contraction. J Urol 1990;144:1293-300. PMID:
1700148
95. Bjorling DE, Jerde TJ, Zine MJ, Busser BW, Saban MR, Saban R. Mast cells mediate the severity of experimental cystitis in mice. J Urol 1999;162:231-6. PMID:
10379792
96. Alexacos N, Pang X, Boucher W, Cochrane DE, Sant GR, Theoharides TC. Neurotensin mediates rat bladder mast cell degranulation triggered by acute psychological stress. Urology 1999;53:1035-40. PMID:
10223502
97. Spanos C, Pang X, Ligris K, Letourneau R, Alferes L, Alexacos N, et al. Stress-induced bladder mast cell activation: implications for interstitial cystitis. J Urol 1997;157:669-72. PMID:
8996395
98. Minogiannis P, El-Mansoury M, Betances JA, Sant GR, Theoharides TC. Hydroxyzine inhibits neurogenic bladder mast cell activation. Int J Immunopharmacol 1998;20:553-63. PMID:
9839659
99. Nurmatov UB, Rhatigan E, Simons FE, Sheikh A. H1 -antihistamines for primary mast cell activation syndromes: a systematic review. Allergy 2015;70:1052-61. PMID:
26095756